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BIOSIMILAR NAMING: A CALL FOR
UNIFORMITY IN A COMPLEX FIELD
INTRODUCTION
he birth of recombinant technology1 has opened a path-
way for a means of producing a variety of therapeutic
proteins and generating the growth of the biopharmaceutical
industry.2 Biopharmaceuticals, or biologics, have become an
important therapeutic option in recent years.3 Biologics repre-
sent “therapeutic proteins, DNA vaccines, monoclonal antibod-
ies, and fusion proteins” that are used to treat autoimmune
disorders and cancers.4 These pharmaceuticals are structurally
complex and are made in living organisms to provide proteins
to treat various diseases, often by genetically engineering liv-
ing cells.5 Because of their complexity, biologics can be heat
sensitive and susceptible to microbial contamination.6 Thus,
they must be maintained in stable storage environments and
administered in a manner that preserves their efficacy in the
human body.7 These inherent characteristics of biologic drugs
make immunogenicity8 a crucial aspect to the success of biolog-
ic products.9
1. Recombinant technology, also known as Recombinant DNA, is the pro-
cess of taking a gene from one organism and inserting the gene into the DNA
of another. This process has revolutionized the pharmaceutical industry. See
Anthony J. Griffiths, Recombinant DNA Technology, ENCYCLOPEDIA
BRITANNICA,
http://www.britannica.com/EBchecked/topic/493667/recombinant-DNA-
technology (last updated Mar. 20, 2014).
2. H. Mellstedt et al., The Challenge of Biosimilars, 19 ANNALSONCOLOGY
411 (2008).
3. See generally id.
4. Kristina M. Lybecker, When Patents Aren’t Enough: Why Biologics Ne-
cessitate Data Exclusivity Protection, 40 WM. MITCHELL L. REV. 1427, 1433
(2014) (quoting Amgen).
5. Id.
6. Jeanne Yang, A Pathways to Follow-on Biologics, 3 HASTINGS SCI. &
TECH. L.J. 217, 222 (2011) (quoting What Are “Biologics” Questions and An-
swers, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTo
bacco/CBER/ucm133077.htm (last updated Aug. 5, 2015)).
7. Id.
8. Immunogenicity is defined as “the propensity of therapeutic proteins to
generate immune responses to itself and to related adverse clinical events.”
Food & Drug Admin., U.S. Dep’t Health and Human Servs., Guidance for
T
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In comparison to the complex nature of biologic drugs, small-
molecule chemical drugs are structurally straightforward and
well known.10 Small-molecule chemical drugs are commonly
associated with most prescription medicines.11 While the Food
and Drug Administration’s (FDA) approval for these types of
small-molecule chemical drugs, both generic and brand, is cost-
ly, there is a certain ease associated with small-molecule ap-
proval that does not exist for biologic and generic biologic ap-
proval.12 Due to the rather simple structure and well-known
synthesis of small-molecule chemicals, generic producers can
easily reproduce these small-molecule drugs.13
In order for the FDA to approve a generic drug, like amoxicil-
lin and simvastatin, which are among the most popular FDA
approved small-molecule generic drugs,14 the drug applicant
must establish that the original drug, commonly referred to as
the reference product,15 and the generic are bioequivalent.16 As
Industry: Immunogenicity Assessment for Therapeutic Protein Products 1
(2014),
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformati
on/guidances/ucm338856.pdf.
9. See Yang, supra note 6, at 236 (noting that upon submission for FDA
approval, biologic applicants must establish the comparability of their drug’s
immunogenicity to that of existing market products).
10. Donna M. Gitter, Informed By The European Union Experience: What
the United States Can Anticipate And Learn From the European Union’s Reg-
ulatory Approach to Biosimilars, 41 SETONHALL L. REV. 559, 560 (2011).
11. Stacey L. Worthy & John F. Kozak, Follow-on Biologics: Protecting
Consumers Through State Pharmacy Law in Light of Recent FDA Actions, 17
QUINNIPIACHEALTH L.J. 207, 207 (2014).
12. Gitter, supra note 10, at 562.
13. Mellstedt et al., supra note 2, at 412.
14. It is estimated that over the past decade generic drugs have saved the
U.S. healthcare system approximately $734 billion. Anthony D. So & Samuel
L. Katz, Opinion, Biologics Boondoggle, N.Y TIMES, Mar. 8, 2010, at A23. On
average, biologic brand-name drugs cost twenty-two times as much as small-
molecule chemical drugs. Id. Herceptin, a breast cancer drug, costs patients
$37,000 a year, and Humira, a drug for treating rheumatoid arthritis and
Chron’s disease, costs $50,000 a year. Id.; see also Michael Bartholow, Top
200 Drugs of 2012, PHARMACY TIMES (July 17, 2013),
http://www.pharmacytimes.com/publications/issue/2013/july2013/top-200-
drugs-of-2012. Thus, the need for cheaper biologic drugs is dire.
15. A reference product may also be called an innovator drug. The term is
used in cases of both traditional chemical drugs and biologic drugs to define
the original invented drug upon which the generic version aims to “piggy-
back.” See Yang, supra note 6, at 233.
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a comparison between the reference product and the generic,
bioequivalence is defined as the absence of a significant differ-
ence between the rate and extent to which the active ingredient
becomes available at the site of drug action.17 Essentially, bioe-
quivalence analyzes whether the two drugs have identical ac-
tive ingredients and produce the same effect in the body.18 One
can establish bioequivalence by demonstrating that the phar-
macokinetic properties of the generic and the reference product
are similar.19 Given the makeup of small-molecule chemical
drugs, it is not difficult to prove bioequivalence by demonstrat-
ing identical chemical composition and similar pharmacokinet-
ics.20 The inherent properties of small-molecule drugs allow the
production of generic drugs to be straightforward, safe, and ef-
ficient.21 Given the complexity of biologic drugs, however, mi-
nute changes in the manufacturing process can result in dras-
tic differences in quality, safety, and efficacy between reference
product and potential biosimilars.22 This makes demonstrating
bioequivalence for potential biosimilars difficult.23
With the patent expirations of a number of biologics in the
coming years,24 there has been an increased interest in the de-
velopment of generic biologics,25 also known as biosimilars, and
a widespread push for biosimilar FDA approval in the United
States.26 While the pressure for the expansion of biosimilar ap-
16. See generally Food & Drug Admin., U.S. Dep’t Health & Human
Servs., Guidance For Industry: Bioavailability & Bioequivalence Studies for
Orally Administered Drug Products – General Considerations (2003) [herein-
after Bioavailability & Bioequivalence Studies],
http://www.fda.gov/ohrms/dockets/ac/03/briefing/3995B1_07_GFI-BioAvail-
BioEquiv.pdf.
17. Id.
18. Id.
19. See id.
20. Worthy & Kozak, supra note 11, at 217.
21. Mellstedt et al., supra note 2, at 412.
22. Gitter, supra note 10, at 561.
23. Worthy & Kozak, supra note 11, at 221.
24. See GOODWIN PROCTER, BIOSIMILARS: A GUIDANCE TO REGULATORY AND
INTELLECTUAL PROPERTY ISSUES 10 (2014).
25. Before the Patient and Affordable Care act was passed in 2010, there
was public pressure to create an abbreviated approval pathway for biosimilar
drugs. Many hoped the development of these biosimilar drugs would substan-
tially reduce the cost of many life-saving biopharmaceutical therapies. See
generally So & Katz, supra note 14.
26. Mellstedt et al., supra note 2, at 411.
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proval is warranted, the FDA must be cautious when imple-
menting regulatory guidelines. Since biologics differ greatly
from small-molecule drugs, biologics have a distinct approval
process.27 Assuming that a biosimilar will be just as safe and
effective as its reference product is not a decision that can be
taken lightly.28
Key players in the pharmaceutical industry have weighed in
on this issue and have expressed concern about biosimilar ap-
proval,29 warning that “seemingly small changes to a biologics
structure . . . may have unintended clinical consequences.”30 In
the late 1990s, such a concern manifested itself in a real life
tragedy. A U.S. manufacturer of the drug erythropoietin31 li-
censed their rights to another manufacturer to produce the
same product in the European Union.32 The EU manufacturer
27. Gitter, supra note 10, at 561.
28. Pamela Jones Harbour, Commissioner, Federal Trade Commission,
Remarks before the American Bar Association Sections of Antitrust and In-
tellectual Property Law’s Conference: Intellectual Property Antitrust – Stra-
tegic Choices, Evolving Standards, and Practical Solutions (June 14, 2007)
[hereinafter Harbour ABA Remarks], (transcript available at
https://www.ftc.gov/sites/default/files/documents/public_statements/competiti
ve-implications-generic-biologics/070614genbio_0.pdf).
29. Companies, such as brand-name biologic producer Sanofi, have ex-
pressed concern about the biosimilar approval process. Critics may argue
that companies, like Sanofi, only have an interest in preserving their monop-
oly on the biologics market; however their concerns are not unfounded. In
fact, the Pharmaceutical Research and Manufacturers of America (PhRMA)
released a set of overarching principles on biosimilar approval. Approval
Pathway for Biosimilar and Interchangeable Biological Products: FDA Public
Hearing, (Nov. 2–3, 2010) (statement of Marie A. Vodicka, PhRMA Associate
Vice President of Scientific and Regulatory Affairs),
http://www.phrma.org/sites/default/files/pdf/110210_phrma_biosimilars_publi
c_hearing_testimony_final.pdf. PhRMA takes a conservative stance on bio-
similar approval and stresses the importance of patient safety above all. Id.
30. Robert J. Mattaliano, Group VP Biologics Department, Genzyme Cor-
poration, Remarks before FDA Advisory Committee on Pharmaceutical Sci-
ence and Clinical Pharmacology, A PhRMA Member View on Biosimilars:
Analytical and Quality Considerations, at 12 (Aug. 8, 2012),
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMate
ri-
als/Drugs/AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmaco
logy/UCM315764.pdf.
31. Erythropoeitin is a hormone and biologic drug that promotes red-blood-
cell growth. Wolfgang Jelkman, Regulation of Erythropoietin Production, 589
J. PHYSIOLOGY. 1251, 1251 (2011).
32. Worthy & Kozak, supra note 11, at 242.
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used the same methodology to produce the drug, making only
incidental changes.33 However, EU patients who used the drug
developed pure red cell aplasia, “a life threatening condition”
wherein the bone marrow stops producing red blood cells.34 As
a result, multiple patients died while others became perma-
nently dependent upon blood transfusions.35
It is clear that biosimilars are not just generic versions of bio-
logic drugs.36 The true complexity of a biosimilar’s structure
makes it much more difficult to create biosimilar regulatory
pathways that can ensure the safety of consumers.37 The pro-
cess for approving a biosimilar requires greater analysis and
consideration than traditional generic drug approval.38 Due to
the lack of experience in regulating these drugs, authorities
have moved cautiously, heavily scrutinizing the first wave of
biosimilar applications.39
The United States is certainly not the first to provide a path-
way for biosimilar approval.40 The EU, India, Japan, and South
Korea have already adopted a regulatory framework for biosim-
ilar approval.41 The EU began developing their framework in
2005, Japan and South Korea in 2009, and India in 2012.42 The
framework varies slightly from country to country.43 However,
they generally employ the same approach to ensure that phar-
macokinetic studies establish the substantial similarity be-
tween the reference product and the biosimilar.44 With the de-
velopment and implementation of multiple regulatory frame-
works, international organizations, such as the World Health
33. Id.
34. Id. at 209. Pure red cell aplasia resulted from an allergic reaction to
biologics. Id.
35. Id.
36. See GOODWIN PROCTER, supra note 24, at 1.
37. See Harbour ABA Remarks, supra note 28. See generally GOODWIN
PROCTER, supra note 24.
38. Id. at 1.
39. Id.
40. FENWICK & WEST LLP, A COMPARISON OF US AND EU BIOSIMILARS
REGIME 3 (2012), https://www.fenwick.com/FenwickDocuments/01-06-
12_Comparison_US_EU_Biosimilars_Regimes.pdf.
41. See GOODWIN PROCTER, supra note 24, at 48.
42. Id.
43. Id.
44. Id.
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Organization (WHO), will be tasked with ensuring there are
cohesive guidelines for any residual concerns that develop.45
With the increase in the number of biosimilars available, the
process of naming biosimilars has become an important regula-
tory concern; causing countries to develop various methods of
naming approved biosimilars.46 Some regulatory bodies use the
international nonproprietary name (INN) of the reference
product, others such as regulatory bodies in Australia and Ja-
pan, attach a short and separate qualifier.47 In the United
States, brand companies have proposed that the biosimilars
should receive a unique INN.48 However, a lack of uniformity in
nomenclature would result in the same biological medicine
having different meanings in different areas of the world.49 In
attempts to avoid the promulgation of separate and distinct
national qualifier systems, several regulatory authorities have
requested that the WHO’s INN Programme develop a universal
nomenclature system applicable to biosimilars.50
This Note will analyze the current U.S. and EU approach for
defining the necessary measures in demonstrating biosimilari-
ty to a reference product. Part I will lay the foundation for bio-
similar regulatory approval by examining the regulatory pro-
cess and legislative history of the FDA’s small-molecule generic
drug approval process. Additionally, Part I will discuss the leg-
islative history of approving biopharmaceutical drugs and the
FDA’s recent biosimilar approval guidelines. This analysis will
demonstrate the importance of recent legislation and its effects
on the biopharmaceutical market.
45. See World Health Organization [WHO], Biological Qualifier: An INN
Proposal, at 2–3, INN Working Doc. 14.342 (July 2014) [hereinafter Biologi-
cal Qualifier Proposal],
http://www.who.int/medicines/services/inn/bq_innproposal201407.pdf.
46. Id. (proposing a short and separate qualifier, referred to as a “BQ,”
which would complement the INN for a biological substance).
47. Id.
48. Id.
49. For example, an epoetin registered in Europe by the EMEA using the
INN, epoetin alfa, was subsequently registered by Australia with an INN-
similar nonproprietary name epoetin lambda. See Biological Qualifier Pro-
posal, supra note 45, at 3.
50. INN experts and the INN Secretariat met in April 2013 and 2015. Id.
Additionally, an INN Expert Group convened in October 2014 and April 2014
to discuss whether the WHO should devise such a program. Id.
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Part II will provide an analysis of the EU’s approach to bio-
similar approval. This analysis will also evaluate both the his-
torical evolution and success of the EU program since its incep-
tion. Part III will examine the concerns with biosimilar nam-
ing. This part will analyze the current naming framework pro-
vided by the EU, United States, and the WHO, and how each
framework will affect the success of the biologics market. Final-
ly, Part IV proposes a framework for future biosimilar naming
in the United States. Ultimately, this Note suggests that in or-
der to successfully promote the growth of the biosimilars mar-
ket and facilitate the true intent of global legislation creating
abbreviated approval pathways for biosimilars, the WHO, to-
gether with the EU and the United States, should ensure bio-
similars are afforded INNs that are identical to their existing
biologic counterpart.
I. THEU.S. APPROACH TO BIOLOGIC AND BIOSIMILAR APPROVAL
This section will discuss the history of the United States’ ab-
breviated approval pathway for generic small-molecule drugs
and the approval pathway for biologic drugs. Further, this sec-
tion will examine the development of the United States’ abbre-
viated approval pathway for biosimilar drugs through the Bio-
logics Price Competition and Innovation Act (BPCIA).
A. The Predecessor: Drug Price Competition and Patent Term
Restoration Act
The United States regulates the manufacture and distribu-
tion of drugs through the FDA pursuant to the Federal Food,
Drug, and Cosmetic Act (FDCA).51 The approval process for
traditional chemical drugs occurs in multiple steps.52 First, ap-
plicants for a new traditional chemical drug submit an Investi-
gational New Drug application (“IND”).53 This application in-
cludes a preclinical phase of developing the chemical drug and
continues with discovery and research.54 After evaluating the
51. DONALD O. BEERS & KURT R. KARST, GENERIC AND INNOVATOR DRUGS: A
GUIDE TO FDA APPROVAL REQUIREMENTS 3 (8th ed. 2013).
52. See generally Yang, supra note 6, at 227–28.
53. Id.
54. During preclinical trials, drug applicants compile data on efficacy, tox-
icity, and pharmacokinetics by testing a drug on animals. When presented to
the FDA, this data gives a broader picture of the drug, which helps determine
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application, the FDA decides whether to grant permission to
conduct clinical trials on humans, which take place in three
phases.55 Phase I tests the drug on a small group of twenty to
one hundred healthy volunteers to determine whether the drug
is safe and effective.56 Phase II is tested on a larger pool of pa-
tients57 and is used to confirm that the drug has the intended
effect.58 Phase III, the most costly, involves several thousand
patients and evaluates the safety and effectiveness of the
drug.59 During Phase III clinical trials, the drug manufacturer
submits what is known as a New Drug Application (“NDA”).60
The FDCA was established to provide a pathway for brand
name drug applicants only. It was not until the 1980s that an
abbreviated approval, or generic, process was formed.61
In 1984, Congress enacted the Drug Price Competition and
Patent Term Restoration Act, colloquially known as the Hatch-
Waxman Act, which amended the FDCA.62 The Hatch-Waxman
Act sought to stimulate generic competition in the traditional
chemical drug market.63 The act did so by providing an abbre-
viated pathway64 that enabled generic drugs to obtain FDA ap-
whether to approve a drug application and allow clinical testing on human
subjects to begin. Id. at 228.
55. Id.
56. Id.
57. In Phase II of the clinical trial process, the drug is administered to
people who suffer from the disease the drug seeks to treat. This pool of people
is different than Phase I, which is administered to healthy people. Id.
58. Yang, supra note 6, at 228.
59. Id.
60. Id. Currently, only 64 percent of the drugs that make it through pre-
clinical trials and Phases I, II, and III are submitted as NDAs. Id.
61. Drug Price Competition and Patent Term Restoration Act (DPCTRA),
Pub. L. No. 98–417, 98 Stat. 1585 (codified as amended in scattered sections
of U.S.C. (1984)).
62. Id.
63. Yang, supra note 6, at 228.
63. Myers Squibb Co. v. Royce Labs., Inc., 69 F.3d 1130, 1133–34 (Fed. Cir.
1995) (noting that the Hatch-Waxman Act represented Congress’ attempt to
“strike a careful balance between the policies of fostering the availability of
generic drugs and of providing sufficient incentives for research on break-
through drugs”).
64. Additionally, otherwise infringing actions are exempt from patent in-
fringement when the actions are related to submissions for FDA approval. 35
U.S.C. § 271(e)(1). This is known as the “Bolar Exemption.” In Roche Prod-
ucts, Inc. v. Bolar Pharmaceutical Co., the court decided that “manufacture,
use, or sale of a patented invention during the term of the patent constituted
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proval.65 The Hatch-Waxman Act created the regulatory
framework to support an abbreviated new drug application
(“ANDA”),66 which is found under § 505(j) of the FDCA.67 Under
§ 505(j), an applicant must prove that its drug is safe and effec-
tive by establishing that it has (1) the same active ingredients,
(2) the same route of administration, (3) the same dosage form,
and (4) the same strength as the reference product.68 If these
four requirements are met, ANDA applicants may rely on the
reference product’s safety and effectiveness to be deemed ther-
apeutically equivalent to the reference product.69 Importantly,
this provision of § 505(j) allows small-molecule generic drug
applicants under the Hatch-Waxman Act to forego the clinical
testing of drugs since the reference drug has already been
proven to be both safe and effective.70
B. The Public Health Service Act’s § 351(a) Pathway
While the FDA approves traditional small-molecule chemical
drugs under the FDCA, biologics receive FDA approval under §
351 of the Public Health Services Act (PHSA).71 This process
entails the submission of a biologics license application (“BLA”)
under § 351(a).72 In order to receive approval, the applicant
must establish that the biologic drug and the manufacturing
product are “safe, pure, and potent.”73 There are no quantified
an act of infringement, even if it was for the sole purpose of conducting tests
and developing information necessary to apply for regulatory approval.” 733
F.2d 858, 861 (Fed. Cir. 1984); see also Erwin Blackstone et al., The Future of
Competition in the Biologics Market, 31 TEMP. J. SCI. TECH. & ENVTL. L. 1, 16
(2012).
65. Yang, supra note 6, at 228.
65. Id.
66. Worthy & Kozak, supra note 11, at 216.
67. See generally DPCTRA, Pub. L. No. 98–417, 98 Stat. 1585 (codified as
amended in scattered sections of U.S.C. (1984)).
68. Id.
69. Worthy & Korzak, supra note 11, at 217.
70. Yang, supra note 6, at 229.
71. 42 U.S.C. § 262; see also Shawn P. Gorman et al., The Biosimilars Act:
The United States’ Entry into Regulating Biosimilars and Its Implications, 12
J. MARSHALL REV. INTELL. PROP. L. 332, 325 (2013).
72. See 21 C.F.R. § 601.2 (2011); see also Gorman et al., supra note 71, at
325.
73. In comparison to the FDCA, the PHSA gives the FDA a greater
amount of regulatory control over manufacturing processes. Given how criti-
cal the manufacturing process is to the safety and efficacy of biologic drugs,
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or measurable standards for “safe, pure, and potent.”74 Instead,
the FDA analyzes each drug application on a case-by-case ba-
sis.75
Not surprisingly, the FDA approval process under the §
351(a) pathway is both timely and expensive.76 However,
pharmaceutical companies invest the time and money to apply
under § 351(a) because of the exclusivity they receive.77 Prior to
2010, applicants under § 351(a) knew that because there was
no abbreviated approval pathway available for biologics, they
would have limited or no competition.78 The barrier for entry
was too high as companies had to invest too much money to re-
ceive approval under § 351(a).79 For those biologics that were
available, the high approval cost made them costly for pa-
tients.80 A pathway, similar to the one for generic drugs under
the Hatch-Waxman Act, was necessary in order to facilitate the
growth of the biosimilar market and the development of cheap-
er biologics.81 The approval process for biosimilars must strike
a balance between the safety and efficacy of the drugs, and the
cost to, and resources of, the generic biologic producers.82
C. The Abbreviated Pathway for Biologic Drugs Established by
the BPCIA
On March 23, 2010, President Barack Obama signed into law
the Patient Protection and Affordable Care Act.83 Title VII,
the FDA’s regulatory control over manufacturing is not surprising. Worthy &
Kozak, supra note 11, at 222; see also 42 U.S.C. § 262(a)(2)(C)(i).
74. Id..
75. Worthy & Kozak, supra note 11, at 222.
76. JOHN R. THOMAS, CONG. RESEARCH SERV., R42890, THE ROLE OF
PATENTS AND REGULATORY EXCLUSIVITIES IN PHARMACEUTICAL INNOVATIONS 15
(2013).
77. Worthy & Kozak, supra note 11, at 215.
78. So & Katz, supra note 14.
79. Id.
80. Id. It is important to note that this op-ed, which was written before the
BCPIA was enacted, relays the landscape of the biologics market before an
abbreviated pathway was available.
81. Implementation of the Biologics Price Competition and Innovation Act
of 2009, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ucm21
5089.htm (last updated Mar. 10, 2011).
82. Yang, supra note 6, at 218.
83. Patient Protection and Affordable Care Act, Pub. L. No. 111–148, 124
Stat. 119 (2010) (codified in scattered sections of 42 U.S.C.).
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Subtitle A of the Act detailed the BPCIA.84 The BPCIA created
an “abbreviated licensure pathway for biological products
shown to be biosimilar to or interchangeable with an FDA li-
censes reference product.”85 The BPCIA sought to amend the
PHSA to provide a regulatory framework for the development
of cheaper biologics to enter the market.86
Under the BPCIA, biosimilar applicants are able to file a
BLA under § 351(k) of the PHSA.87 The new pathway, by com-
paring the biosimilar against a reference product already li-
censed under the full approval process, permits the FDA to ap-
prove a biosimilar based on less clinical data than required by §
351(a).88 Essentially, the BPCIA creates a shorter pathway for
biosimilar approval, which in turn allows for cheaper alterna-
tives to many life-saving biologic medicines.
In order to receive approval under the § 351(k) abbreviated
pathway, the biosimilar applicant must demonstrate that the
biosimilar drug: (1) has the same mechanism of action as the
reference (if known), (2) demonstrates the conditions of use
previously approved for the reference product, (3) utilizes the
same route of administration, dosage form, and strength, and
(4) ensures that the proposed product is manufactured,89 pro-
84. Steven Kozlowski, Presentation to the Advisory Committee for Phar-
maceutical Science and Clinical Pharmacology, Biosimilars – An Update Fo-
cused on Quality Considerations (Aug. 8, 2012),
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMate
ri-
als/Drugs/AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmaco
logy/UCM315764.pdf; see also Patient Protection and Affordable Care Act §
7002.
85. Kozlowski, supra note 84.
86. John Alan Little, Jr., Taking From Trailblazers: Learning From Those
Who Have Gone Before When Approving Biosimilars, 44 GA. L. REV. 1097,
1101 (2010).
87. Gorman et al., supra note 71, at 328; see also Harbour Remarks to
ABA, supra note 28; Suzanne White Junod, Celebrating a Milestone: FDA’s
Approval of a First Genetically Engineered Product, U.S. FOOD & DRUG
ADMIN.,
http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/Selecti
onsFromFDLIUpdateSeriesonFDAHistory/ucm081964.htm (last updated
Apr. 10, 2009). However, not every biologic product is subject to the BPCIA.
For example, human growth hormones and insulin were approved through a
NDA under the FDCA and Hatch-Waxman Act. Id.
88. See generally Gorman et al., supra note 71.
89. Id. at 328; see also Mellstedt et al., supra note 2, at 412 (highlighting
the importance of the manufacturing process of biopharmaceuticals, which in
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cessed, packed, or held in a facility that meets standards for
the maintenance of safety, purity, and potency.90 The BPCIA
defines a biologic as being highly similar to the reference prod-
uct, therefore notwithstanding minor differences in clinically
inactive components; “there are no clinically meaningful differ-
ences between the biological product and the reference product
in terms of the safety, purity, and potency of the product.”91
The FDA released industry guidelines that outline its ap-
proach for defining “similarity.”92 The assessment employs a
spectrum ranging from “highly similar with fingerprint-like
similarity” to “not similar.”93 A biosimilar is given a degree of
similarity based upon the analytical data provided.94 The appli-
cant must submit analytical studies that demonstrate the high-
ly similar features as compared to the reference product, ani-
mal studies, including an assessment of toxicity, and one or
more clinical studies that are sufficient to demonstrate safety,
purity, and potency.95 The clinical studies must demonstrate
that the proposed biosimilar has neither decreased nor in-
creased activity as compared to the reference product.96 In-
creased activity of a biologic product may mean more adverse
side effects, while decreased activity would preclude the prod-
uct from being biosimilar to the reference product.97 Due to the
lack of biosimilar applications in the United States, it is diffi-
cult to get a clear picture on the exact thresholds for these
tests.
turn explains the stringency of production and distribution facility stand-
ards).
90. Since the enactment of BPCIA in 2010, the FDA has released four sets
of guidelines that create a rough blueprint of the biosimilar approval path-
way. While some of these guidelines are vague, the FDA has thoroughly de-
fined the safety, purity, and potency standards that biosimilar applicants
must meet. See 21 C.F.R. § 600.3(p)–(s) (2015); 42 U.S.C. § 262(k)(2)(A)(i)(II)–
(V) (2010).
91. Id.
92. FOOD & DRUG ADMIN., U.S. DEP’T HEALTH & HUMAN SERVS., GUIDANCE
FOR INDUSTRY: CLINICAL PHARMACOLOGY DATA TO SUPPORT A DEMONSTRATION
OF BIOSIMILARITY TO A REFERENCE PRODUCT 5 (2014) [hereinafter CLINICAL
PHARMACOLOGY DATA] (defining the four possible assessments of biosimilar
applications).
93. Id.
94. Id.
95. Gorman et al., supra note 71, at 329.
96. Id. at 331.
97. Id.
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“Interchangeable” is an additional designation given by the
FDA to a biosimilar applicant.98 A product is labeled “inter-
changeable” when the biological product is both biosimilar to
the reference product and produces identical clinical results as
the reference product in any given patient.99 Therefore, when
the biosimilar is administered more than once to a single indi-
vidual, the risk in terms of safety or diminished efficacy of
switching between the reference product and the biosimilar is
not greater than the risk of using the reference product
alone.100 A biosimilar that meets the high burden of being in-
terchangeable “may be substituted for the reference product
without the intervention of the health care provider that pre-
scribed the reference product.”101
D. Incentives to Invest in Biologic Drug Applications
Various federal regulations allow the biologic market to flour-
ish.102 Arguably, the most important regulations are those that
afford exclusivities.103 Exclusivities can be broken down into
two forms: data exclusivity and market exclusivity.104 Data ex-
clusivity gives the reference product a set amount of time of
data protection.105 Companies looking to produce a biosimilar of
the reference product may not have the ability to produce their
own data packaging and need the reference product data for
the development process.106 Thus, data exclusivity can postpone
biosimilar development until the reference product has had a
certain number of years of exclusivity.107 The second form,
98. 42 U.S § 262(k)(4)(A)(i)–(ii) (2010).
99. Id.; see also Gorman et al., supra note 71, at 332.
100. 42 U.S § 262(k)(4)(B).
101. 42 U.S § 262(i)(3).
102. Prior to the passing of the BCPIA, exclusivities and incentives were
not incredibly important because biologic drug manufacturers had no poten-
tial competition with a generic version. See generally Erwin A. Blackstone et
al., The Economics of Biosimilars, 6 AM. HEALTH&DRUG BENEFITS 469 (2013)
[hereinafter Economics of Biosimilars].
103. Serge Lapointe & Julie-Anne Archambault, Importance of Non-Patent
Exclusivities in the Life Cycle of Management of Pharmaceuticals, 27 CAN.
INTELL. PROP. REV. 115, 115 (2011).
104. See generally Gorman et al., supra note 71, at 337.
105. THOMAS, supra note 76, at 4.
106. Id. at 4–5.
107. Id.
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market exclusivity, ensures that the reference product has a
certain number of years on the market without competition.108
The BPCIA established two separate sections of exclusivity
for biologic applicants,109 or the reference product, that undergo
the full licensing application through § 351(a).110 First, no other
applicant can submit an application under § 351(k) until four
years after the reference product was first licensed under §
351(a).111 This period mirrors market exclusivity and prevents
any biosimilar applicant from applying for FDA approval until
after those four years have ended.112
Second, the FDA cannot approve a biosimilar application un-
der § 351(k) until twelve years after the reference product was
first licensed under § 351(a).113 The BPCIA failed to expressly
define whether this twelve-year regulatory exclusivity period
referred to data or marketing exclusivity.114 Members of Con-
gress drafted letters to the FDA explaining that the twelve-
year period acted as data exclusivity.115 These letters explained
that it was intended that the regulatory exclusivity period
“protects the FDA from allowing another manufacturer to rely
on the data of an innovator to support another product . . . it
does not prohibit or prevent another manufacturer from devel-
oping its own data to justify FDA approval of competitive prod-
uct.”116 Therefore, during the twelve years of data exclusivity,
companies seeking to produce a biosimilar may not use any da-
ta from the reference product to assist in their biosimilar de-
108. Id.
109. The two separate sections of exclusivity run concurrently with a start
date of the day the reference product was first licensed. U.S. DEP’T HEALTH &
HUMAN SERVS., BIOSIMILARS: ADDITIONAL QUESTIONS AND ANSWERS REGARDING
IMPLEMENTATION OF THE BIOLOGICS PRICE COMPETITION AND INNOVATION ACT
OF 2009 (2015) [hereinafter BIOSIMILARS Q&A].
110. Id.
111. Id.
112. Id.
113. THOMAS, supra note 76, at 8–9.
114. Id. at 9.
115. Letter from Kay Hagan, Senator of N.C., et al., to Dr. Margaret Ham-
burg, Comm’r, Food & Drug Admin. (Jan. 7, 2011), http://www.ip-
watch.org/weblog/wp-content/uploads/2011/01/H-E-H-Letter-1-7-11-Senate-
Biologics-letter-to-FDA.pdf.
116. Letter from Anna G. Eshoo, Representative Cal., et al. to Food & Drug
Admin., Division of Dockets Management (Dec. 21, 2010),
http://www.hpm.com/pdf/EIB%20Ltr%20FDA%20DEC%202010.pdf.
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velopment.117 This period of time is relatively long, and in an
effort to ensure there is no evergreening,118 the law states that
an additional twelve years will not be given for reference prod-
ucts for supplemental or subsequent applications that make
minor changes.119 While the first approved biosimilar drug does
not retain any right to exclusivity, another biosimilar designa-
tion, known as interchangeable, is granted between twelve and
forty-two months of exclusivity.120
E. The First Filing of a Biosimilar Application Under the
§ 351(k) Abbreviated Pathway
While the BPCIA established a pathway for biosimilar ap-
proval back in 2010, the FDA did not receive its first applica-
tion until 2014.121 On July 24, 2014, Sandoz Inc.122 announced
that the FDA had accepted their filing for its biosimilar.123
Sandoz Inc.’s application was for a proposed filgrastim124 and is
comparable to Amgen’s Neupogen,125 since then the FDA has
received several INDs for biosimilars.126 However, Sandoz Inc.’s
117. 42 U.S.C. § 262 (k)(7)(B) (2010).
118. “Evergreening” is an extension of a drug’s exclusivity period. Worthy &
Kozak, supra note 11, at 223.
119. Id.
120. See 42 U.S.C. § 262(k)(6) (2010).
121. See Press Release, FDA Accepts Sandoz Application for Biosimilar Fil-
grastim, SANDOZ (July 24, 2014), http://www.sandoz-
biosimi-
lars.com/en/mediacenter/press_releases/140724_FDA_accepts_Sandoz_applic
ation_for_biosimilar_filgrastim.shtml.
122. Sandoz is the generic pharmaceutical division of Novartis and is a
global leader in the generic pharmaceutical sector. See SANDOZ INC.,
http://www.sandoz.com (last visited Jan. 25, 2015).
123. See generally Alexander Gaffney, Sandoz First Company to File for
Biosimilar Approval in U.S. Under New Pathway, REG. AFF. PROF. SOC’Y:
NEWS (July 24, 2014), http://www.raps.org/Regulatory-
Focus/News/2014/07/24/19818/Sandoz-First-Company-to-File-for-Biosimilar-
Approval-in-US-Under-New-Pathway/.
124. Filgrastim is a granulocyte-colony stimulating factor that is produced
by recombinant DNA technology. See Sandoz, FDA Oncologic Drugs Advisory
Committee Meeting: Zarxio 9 (Jan. 7, 2015), available at
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMate
rials/Drugs/OncologicDrugsAdvisoryCommittee/UCM428782.pdf.
125. Neupogen is an FDA-approved treatment used to decrease the rate of
infection in patients with nonmeyloid malignancies who are already receiving
chemotherapy. Id.
126. See generally Gaffney, supra note 123.
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application is the first to be submitted for full market approval
under the § 351(k) abbreviated pathway, created in the BPCI
Act, instead of the traditional § 351(a) pathway.127
On January 7, 2015, an independent panel unanimously ad-
vised the FDA to approve Sandoz Inc.’s biosimilar, referred to
as EP2006.128 The advisory committee stated that the compara-
tive analytical data demonstrated EP2006 was highly similar
to Neupogen, “notwithstanding minor difference in clinically
inactive components.”129 The briefing report from the inde-
pendent panel closely mirrors the guidance provided by the
FDA in its May 2014 guideline.130 This guidance document sets
out the four-part spectrum for biosimilarity that ranges from
not similar all the way to highly similar with fingerprint-like
similarity.131 Additionally, the guidance document provides di-
rection for the development of clinical pharmacology data that
would support the showing of an application as biosimilar.132 It
appears that the panel closely used the FDA’s guidance docu-
ment to make their decision on EP2006. This insight will help
future applicants navigate what they will have to present to
the FDA.
Not only did the panel determine EP2006 was highly similar
to Neupogen, they determined that EP2006 should be approved
for all five of its indications.133 In their application, Sandoz Inc.
requested to be approved for labeling for the following five indi-
cations: “1. Cancer patients receiving myelosuppressive chemo-
therapy, 2. Patients with acute myeloid leukemia receiving in-
127. Id.
128. Lisa L. Mueller, Inching Closer to the First Biosimilar Approval in the
United States, NAT’L L. REV. (Jan. 12, 2015),
http://www.natlawreview.com/article/inching-closer-to-first-biosimilar-
approval-us.
129. See Sandoz, supra note 124.
130. See FOOD & DRUG ADMIN., FDA Briefing Document: Oncologic Drugs
Advisory Committee Meeting (2015) [hereinafter ODAC Brief],
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMate
rials/Drugs/OncologicDrugsAdvisoryCommittee/UCM428780.pdf. See general-
ly CLINICAL PHARMACOLOGYDATA, supra note 92, at 5.
131. Kozlowski, supra note 84.
132. ODAC Brief, supra note 130.
133. Sanya Sukduang et al., Zarxio’s Approval: Some Insights and Unan-
swered Questions Regarding the Future of U.S. Biosimilars, FINNEGAN (Mar.
24, 2015),
http://www.finnegan.com/resources/articles/articlesdetail.aspx?news=f351481
9-0f2a-4db0-b166-a8efb4ca6ef9.
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duction or consolidation chemotherapy, 3. Cancer patients re-
ceiving bone marrow transplant, 4. Patients undergoing pe-
ripheral blood progenitor cell collection, and 5. Patients with
severe chronic neutropenia.”134
The panel approved all the requested indications through a
method135 called “extrapolation.”136 Essentially, extrapolation is
where Sandoz Inc. provides evidence that the most sensitive
indication, in this case number one above, is highly similar to
the reference product.137 Then, using the “totality of the evi-
dence,”138 the panel may approve EP2006 for the remaining
four indications.139 With the panel’s unanimous approval,140 the
pharmaceutical industry, as well as American patients and
physicians, awaited the final word from the FDA. On March 6,
2015, the FDA took the panel’s advice and approved Sandoz’s
biosimilar Zarxio.141
II. THE EU APPROACH TO BIOLOGIC AND BIOSIMILAR APPROVAL
In 2003, the EU passed a distinct regulatory process to ap-
prove biosimilars.142 This legislation empowered the European
Medicines Agency (“EMEA”) to release guidelines for approval
of biologic products.143 Since then, the EMEA’s Committee for
134. Id.
135. While extrapolation involves approval of a drug for indications for
which it has not been clinically tested, this method still requires applicants to
make a showing that, given the comparability to the reference product, it is
reasonable to extend the approval to other specified indications. See Gitter,
supra note 10, at 589.
136. Sandoz, supra note 124.
137. Id.
138. The FDA has established that they intend to use a “totality of the evi-
dence” approach. Such an approach would permit some sponsors prove bio-
similarity despite formulation or minor structural differences, so long as no
clinically meaningful differences exist. FOOD & DRUG ADMIN., U.S. DEP’T OF
HEALTH & HUMAN SERVS. GUIDANCE FOR INDUSTRY: SCIENTIFIC
CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY TO A REFERENCE PRODUCT
8 (2014) [hereinafter DEMONSTRATING BIOSIMILARITY].
139. Sandoz, supra note 124.
140. SeeMueller, supra note 128.
141. Sabrina Tavernise & Andrew Pollack, F.D.A. Clear “Biosimilar” Medi-
ation, Its First Ever, N.Y. TIMES, Mar. 7, 2015, at B1.
142. Yang, supra note 6, at 231.
143. Ingrid Kaldre, The Future of Generic Biologics: Should the United
States “Follow-On” the European Pathway?, DUKE L. & TECH. REV., no. 9,
2008, ¶ 20, available at
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Medicinal Products for Human Use (“CHMP”) has been the
main force behind these regulatory guidelines.144 The CHMP’s
guidelines are effective throughout the twenty-seven EU-
member states.145 The EMEA approved its first biosimilar in
2006 and since then has approved a total of twenty biosimi-
lars.146
A. Europe’s Success Approving Biosimilar Applications
Through an Abbreviated Pathway
The EMEA approves biosimilars through the abbreviated
pathway on a case-by-case basis.147 The EMEA has produced
various general guidelines for such biosimilar applications. The
three essential requirements are as follows: (1) the provisions
of the requisite preclinical and clinical data, (2) a comparability
exercise to show biosimilarity in quality, efficacy, and safety,
and, (3) product specific pharmacovigiliance and risk-
management plans to monitor potential immunogenicity.148
The abbreviated pathway mandates a showing of clinical trial
data to ensure that the biosimilar is both safe and effective.149
Therefore, the success of an abbreviated approval for a biosimi-
lar is heavily dependent upon the ability to characterize the
biosimilar and demonstrate the similar nature between the
reference product and the biosimilar.150 However, the EMEA
does retain the discretion to request a “full array of preclinical
http://scholarship.law.duke.edu/cgi/viewcontent.cgi?article=1184&context=dlt
r.
144. FENWICK & WEST LLP, supra note 40, at 3; see also Huub Schellekens,
Biosimilar Therapeutics – What Do We Need To Consider?, NEPHROLOGY
DIALYSIS PLUS, at i31 (2009).
145. Gitter, supra note 10, at 569.
146. See GOODWIN PROCTER, supra note 24, at 46.
147. FENWICK&WEST LLP, supra note 40, at 2.
148. Risk-management plans are used to monitor the effects of the biosimi-
lar on patients in the marketplace. It is undisputed by both the FDA and the
EMEA that monitoring immunogenicity and establishing risk-management
plans are crucial to the success of biosimilars in the market. Gitter, supra
note 10, at 570–71, & 571 n.65.
149. FENWICK&WEST LLP, supra note 40, at 2.
150. Gitter, supra note 10, at 569.
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and clinical data if the biologic’s structure is too complex to es-
tablish equivalence adequately.”151
The EMEA and the FDA provide comparable definitions of
biosimilarity.152 The EMEA states that a biosimilar contains a
version of the active substance of an already authorized refer-
ence product, and is similar to the reference product in terms of
quality, safety, or efficacy.153 In their most recent guideline154
the EMEA explains that
if the biosimilar comparability exercise indicates that there
are relevant differences between the intended biosimilar and
the reference medicinal product making it unlikely that bio-
similarity will be established, a stand alone development155 . .
. should be considered.156
The EMEA indicates that previously published information,
alone, will not be sufficient for approval.157 Therefore, extensive
comparability will be required in order to show the similarities
between the biosimilar and the reference product.158 Compara-
151. Joyce Wing Yan Tam, Biologics Revolution: The Intersection of Bio-
technology, Patent Law, and Pharmaceutical Regulation, 98 GEO. L.J. 535,
548 (2010).
152. The FDA defines a biosimilar in further detail than the EMEA. In an
expansion on the EMEA’s definition, the FDA distinguishes that “a biosimilar
is a biological product that is highly similar to a U.S. licensed reference bio-
logical product notwithstanding minor differences in clinically inactive com-
ponents.” See CLINICAL PHARMACOLOGYDATA, supra note 92, at 5.
153. Eur. Medicines Agency, Guideline on Similar Biologic Medicinal Prod-
ucts, EMEA/CHMP/437/04 Rev 1, at 4 (Oct. 23, 2014) [hereinafter Guideline
on Similar Biologic Medicinal Products],
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/
2014/10/WC500176768.pdf.
154. The EMEA released a draft update of their guideline in May 2013.
This version is intended to update the EMEA’s October 2005 guideline on
biosimilarity. See Eur. Medicines Agency, Guideline on Similar Biologic Me-
dicinal Products, EMEA/CHMP/437/04, at 6 (May 22, 2013), available at
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/
2013/05/WC500142978.pdf.
155. A stand-alone development means that the company should attempt to
obtain approval for the biologic drug on its own, and not as a biosimilar of an
already established reference product. For example, in the United States, a
stand-alone development would be applying for approval through the § 351(a)
pathway instead of the § 351(k) pathway. Id.
156. Id.
157. Id.
158. Id.
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bility tests are typically stepwise procedures that start with
pharmacokinetic and pharmacodynamic studies.159 While the
EMEA does not expect the biosimilar and the reference product
to have identical attributes, the EMEA suggests that appli-
cants use pharmacokinetic studies to explore the difference in
the drugs and compare the products in a population where pos-
sible clinical difference may be best observed.160
The final consideration by the EMEA is postmarket monitor-
ing.161 As previously explained, immunogenicity is unpredicta-
ble and incredibly important for consumer welfare.162 In the
EU, postmarketing monitoring is required to assess the poten-
tial immunogenicity of the biologic drug.163 Often, postmarket-
ing monitoring is referred to as pharmacovigilance.164 This de-
scribes the “detection, assessment, understanding, and reten-
tion of adverse effects after the launch of a product onto the
market.”165 Many factors, such as presence of impurities, struc-
tural modifications resulting from manufacturing or storage,
administration techniques, and patient characteristics can af-
fect the immunogenic potential and therefore makes it impos-
sible to predict the immunogenicity in a patient.166 Because of
the abbreviated approval pathway, there tends to be limited
clinical data about the safety risks of biosimilars, which makes
pharmacovigilance crucial.167
The pharmacovigilance program established by the EU is
slightly different than the program anticipated by the United
States. The program was established for all pharmaceuticals,
both chemical and biologic, and contains several components.168
The first component allows healthcare professionals to report
suspected adverse reactions through the EudraVigilance net-
work.169 Second, the EMEA requires drug manufacturers, dur-
ing their approval process, to develop and implement their own
159. See Gorman et al., supra note 71, at 329.
160. Guideline on Similar Biologic Medicinal Products, supra note 153, at
6.
161. Schellekens, supra note 144, at 32.
162. Id.
163. Gitter, supra note 10, at 573.
164. Schellekens, supra note 144, at 32.
165. Id.
166. Gitter, supra note 10, at 573.
167. SeeMellstedt et al., supra note 2, at 415–16.
168. Gitter, supra note 10, at 574.
169. SeeMellstedt et al., supra note 2, at 416.
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pharmacovigilance plans.170 Applicants for market authoriza-
tion must provide the EMEA with a risk-management plan.171
Each risk-management plan must establish a proactive ap-
proach that market authorization applicants will undertake to
identify and manage potential safety risks.172
B. Incentives to Invest in Biologic Drug Applications
The EU has exclusivity incentives very similar to those found
in the United States.173 For a reference drug, the EU awards a
total of ten years of exclusivity.174 The first eight of those years
are data exclusivity, and the last two are market exclusivity.175
Comparatively, the EU provides reference products with more
data protection than the United States.176 The EMEA does not
have the authority to designate interchangeability.177 In fact,
the Executive Director of the EMEA, Thomas Lonngren, has
taken the position that “[i]t is not possible [the EMEA] would
guarantee a biosimilar is interchangeable (with its origina-
tor).”178 The EU leaves the regulation of substitution for each
individual member nation.179 In 2007 the EMEA declared that
“[s]ince biosimilar and biological reference medicines are simi-
lar but not identical, the decision to treat a patient” with either
a reference product or a biosimilar should be reserved for
healthcare professionals.180
As of 2011, France and Spain had enacted legislation that
banned automatic substitution of a biosimilar for the reference
products without the express consent of the prescribing
170. Id.
171. Id.
172. Id.
173. Gorman et al., supra note 71, at 340.
174. Id.
175. Id.
176. THOMAS, supra note 76, at 4.
177. Phani Kishore Thimmaraju et al., Legislations on Biosimilar Inter-
changeability in the US and EU – Developments Far From Visibility, GABI
ONLINE (June 1, 2015), http://www.gabionline.net/Sponsored-
Articles/Legislations-on-biosimilar-interchangeability-in-the-US-and-EU-
developments-far-from-visibility; see also Gitter, supra note 10, at 582.
178. Nick Smith, EMEA “Will Not Guarantee” that Biosimilars are Inter-
changeable with Originator, APM HEALTH EUR. (July 21, 2006, 4:00 PM),
http://www.apmhealtheurope.com/print_story.php?numero=3250.
179. Gitter, supra note 10, at 581.
180. Id.
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healthcare provider.181 However, in 2014, France introduced
legislation that would allow the substitution of a biosimilar for
a reference product as long as the prescribing healthcare pro-
vider did not explicitly mark the prescription as non-
substitutable.182
Since the beginning of the EMEA’s approval of biosimilars,
there have been many success stories. For example, Sandoz
Inc.’s EP2006, the drug approved unanimously by the FDA
panel was first approved in Europe in 2009 as Zarzio.183 Addi-
tionally, the EMEA has approved Sandoz’s Omnitrope, a bio-
similar version of the reference product Genotropin, for indica-
tions in which clinical trials have not been evaluated.184 The
EMEA, similar to the FDA panel, has used extrapolation of
clinical data to find the biosimilar may be used for multiple in-
dications.185 In 2009, it was estimated that biosimilars saved
$1.4 billion in the EU.186
III. THE SUCCESS OF THE BIOSIMILARMARKETDEPENDS ON THE
NAMING OF BIOSIMILAR PRODUCTS
The name of a biological drug carries serious implications for
the FDA’s faith in its success. The name conveys to clinicians
whether or not the biologic has met certain regulatory criteria
and is considered to be biosimilar. If the name does not convey
such similarity it is likely to limit access to these low-cost, safe,
and effective drugs.
Typically, drugs have two names: a nonproprietary name and
a brand name. A common example is the pain medicine Ad-
vil™, which also has a nonproprietary name ibuprofen.187 On
181. Id.
182. France to Allow Biosimilars Substitution, GABI ONLINE (Feb. 21, 2014),
http://gabionline.net/Policies-Legislation/France-to-allow-biosimilars-
substitution.
183. Sabrina Tavernise, For First Time, F.D.A. Panel Approves Generic
Copy of Costly Biologic Drug, N.Y. TIMES, Jan. 7, 2015, at B3.
184. Guillermina Forno & Eduardo Orti, Biosimilars: Current Situation and
Future Expectations, 3 EUR. J. RISK&REG. 213, 214 (2012).
185. Id.
186. Id.
187. FDA Approved Drug Products Containing Ibuprofen, U.S. FOOD &
DRUG ADMIN.,
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=
Search.SearchAction&SearchType=BasicSearch&SearchTerm=IBUPROFEN
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pharmacy shelves there are many generic versions of Advil
that have different brand names, however each product shares
the same nonproprietary name—ibuprofen.188 The nonproprie-
tary names establish a language amongst clinicians and phar-
macists that identify the expected “active ingredient” of a
product.189 Of course, Advil is a traditional small drug, and
therefore does not produce the same complexities as various
biologic products.190 However, the importance of naming does
not change from traditional small drugs to biologics. Whether
the product is a traditional small-molecule drug or biologic
product, clinicians, pharmacists, and even patients rely on
product naming when choosing, dispensing, and taking medica-
tions.
A. The WHO’s Attempt to Unify a Biosimilar Naming Scheme
The WHO oversees the global INN system. INNs identify the
active ingredients in pharmaceutical substances.191 Since its
establishment in 1953, the INN has established approximately
seven thousand names.192 The INN system seeks to provide
healthcare providers with a universally available designated
name to identify each pharmaceutical.193 A universal INN is
crucial to clear identification, safe prescription, and dispensing
of medicines to patients.194
(listing various brand-name drugs contain ibuprofen as its active ingredi-
ents).
188. Id.
189. The right column of the chart on the FDA’s website is denoted “active
ingredient.” Id.
190. The FDA Application number for 200 milligram Advil Tablets is NDA
#018989. See History and Information Related to 200 Milligram Oral Tablets
of Advil, U.S. FOOD & DRUG ADMIN.,
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=
Search.Overview&DrugName=ADVIL. This indicates that Advil was ap-
proved as a traditional small molecule drug, not a biologic, which would have
a BLA number.
191. Gitter, supra note 10, at 586.
192. Programme on Int’l Nonproprietary Names, World Health Org.,
GUIDELINES ON THE USE OF INTERNATIONAL NONPROPRIETARY NAMES FOR
PHARMACEUTICAL SUBSTANCES 1, Doc No. WHO/PHARMS/NOM/1570 (1997)
[hereinafter INN Guideline],
http://apps.who.int/medicinedocs/pdf/h1806e/h1806e.pdf.
193. Id.
194. Id.
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Additionally, INN helps facilitate clear communication and
the exchange of information amongst healthcare providers and
scientists worldwide.195 Pharmaceuticals that come from the
same therapeutic or chemical class are usually given names
with the same stem.196 This assists healthcare providers and
pharmacists with recognition of the substance.197 The use of the
INN designation is elected by each nation that chooses to use
it, and its use is widespread.198 With the growth of biologic
drugs and the development of abbreviated pathways for biosim-
ilars, regulatory bodies such as the FDA and EMEA have de-
veloped new regulatory methods to establish a universal bio-
similar market.199 However, one issue has not been entirely
settled and in fact has garnered much attention as of late.200
The next big issue with the development of the biosimilar mar-
ket is whether biosimilars should be given the same INN as the
brand-name biologic.
In July 2014, the WHO released a draft of their proposed
stance on biologic naming,201 and invited comments and sug-
gestions on the proposal.202 The intended purpose of this pro-
posal was to receive feedback from interested parties.203 The
proposal suggested that applicants request a Biological Qualifi-
er to complement the INN from the INN Secretariat.204 A Bio-
195. Id.
196. INN GUIDELINE, supra note 192, at 1.
197. Id.
198. INN GUIDELINE, supra note 192, at 33. For example, national names
such as the British Approved Names (BAN), the Denominations Communes
Francasises (DCF), the Japanese Adopted Names (JAN), and the United
States Accepted Names (USAN) are identical to the INN.
199. Ed Silverman, What’s in a name? WHO Issues Proposal for Biosimilar
Names, WALL ST. J., (Aug. 1, 2014, 10:25 AM),
http://blogs.wsj.com/pharmalot/2014/08/01/whats-in-a-name-who-issues-
proposal-for-biosimilar-names/.
200. Id.
201. Biological Qualifier Proposal, supra note 45, at 1.
202. Id.
203. Id.
204. Id.; at 2. In October 2015, the WHO released a final proposal for Bio-
similar naming. This final proposal defined the Biological Qualifier as a “code
formed of four random constants in two 2-letter blocks separated by a 2-digit
checksum.” World Health Organization [WHO], Biologic Qualifier: An INN
Proposal, at 2, INN Working Doc. 14.342 (October 2015),
http://www.who.int/medicines/services/inn/WHO_INN_BQ_proposal_2015.pdf
?ua=1.
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logical Qualifier would be an alphabetic code assigned at ran-
dom to a biological active substance manufactured at a speci-
fied site.205 The scheme would be applicable to all biological ac-
tive substances to which INN are assigned.206 The Biological
Qualifier would not be part of the INN, but instead would be
used to complement the INN and uniquely identify directly, or
indirectly, the manufacturer and the manufacturing site of the
active substance in a biological product.207 This proposal
emerges from a period of debate amongst regulators across the
globe.208
B. The United States and Europe: A Naming Conundrum
The BPCIA does not address what nomenclature the FDA
should apply to biosimilars; thus sparking debate about what
the naming of biosimilars should look like.209 Back in 2006, the
FDA outlined its stance in a statement to the WHO.210 In this
statement, the FDA clearly supported the idea of biosimilars
having INNs identical to the reference product.211 The FDA
stated that it would be preferable that “INNs continue to be
205. Biological Qualifier Proposal, supra note 45, at 5.
206. Id. at 4.
207. Id.
208. Id. at 1.
209. Patient Protection and Affordable Care Act, Pub. L. 111–148, §§ 7001–
03 129 Stat. 119, 804–821. Notably, the word “name” is not used once in the
BPCIA. This distinguishes the BPCIA from the Hatch-Waxman Act, which
mandated that ANDAs have labels identical to the reference product. See
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j)(2)(A) (2015).
210. The FDA has since removed this statement from its website. While
there has been no formal press release that the FDA has changed its position
on this topic, some have interpreted the statement’s removal as a tacit ad-
mission of a changed stance. Biosimilar Naming Debate Intensifies, GABI
ONLINE (Nov. 22, 2013), http://gabionline.net/Biosimilars/General/Biosimilars-
naming-debate-intensifies; see also US FDA Considerations: Discussion by
National Regulatory Authorities with World Health Organization (WHO) On
Possible International Non-proprietary Name (INN) Policies for Biosimilars,
U.S. FOOD & DRUG ADMIN. (Sept. 1, 2006),
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelo
pedandAp-
proved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/uc
m375086.htm.
211. Id.
318 BROOK. J. INT’L L. [Vol. 41:1
granted based only on molecular characteristics and pharmaco-
logical class of the active ingredient(s).”212
However, in August 2015, the FDA published industry guid-
ance on the Nonproprietary Naming of Biological Products.213
This FDA guidance explains that the main concern in regards
to biosimilar naming is patient safety, and that biological
product naming must do all it can to prevent inadvertent sub-
stitution of biological products.214 The FDA states that a failure
to employ such a naming convention could lead to unintended
switching of biological products that have not been deemed in-
terchangeable.215 The FDA adopts a scheme similar to the
WHO and suggests “the nonproprietary name includes a dis-
tinguishing suffix for biological products that have not been
determined to be interchangeable.”216 Essentially, the name
will be divided into two separate parts, the nonproprietary
name, and the suffix. For example, products sharing the INN
“replicamab” would be named “replicamab-cznm” or “repli-
camab-hixf.”217
The FDA specifically addresses interchangeable products in
this naming guidance. It suggests that interchangeable prod-
ucts would either have both an INN and a suffix, like biosimi-
lars, or a suffix that is shared with the reference product.218
The FDA approves a biosimilar application to be interchangea-
ble if it is found to be biosimilar to the reference product and
produce clinical results identical to the reference product in
any given patient.219 Therefore, an interchangeable biosimilar
may be substituted for a reference product without any risk to
immunogenicity. If the FDA chooses to provide an interchange-
able biosimilar product with a different suffix than the refer-
ence product, it is removing all incentives for drug companies
to research and develop a biosimilar drug that is so advanced it
212. Id.
213. U.S. Food & Drug Admin., U.S. Dep’t Health & Human Servs.,
Nonproprietary Naming of Biological Products: Guidance for Industry (2015)
[hereinafter Naming Guidance],
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformati
on/guidances/ucm459987.pdf.
214. Id. at 1.
215. Id.
216. Id.
217. Id. at 8.
218. Id. at 9.
219. 42 U.S.C. § 262(k)(4)(B) (2010).
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has been proven to have identical clinical results to the refer-
ence product. This is just one example of how the FDA’s new
naming guidance will thwart the expansion of the biosimilar
market.
Prior to the FDA’s guidance, companies and organizations
submitted petitions to the FDA outlining their vision for bio-
similar naming.220 It is not surprising where generic and brand
name pharmaceutical companies fall in this debate.221 Brand-
name drug makers and biotechs would like to see biosimilars
have a unique name to distinguish the biosimilar from the ref-
erence product.222 The reasoning is that different names would
make it easier to track adverse events,223 and would be less
confusing for healthcare providers and pharmacists.224 Addi-
tionally, brand companies argue that assigning the biosimilar
and the reference product the same INN will encourage treat-
ing all biosimilars as biogeneric equivalents.225
However, companies that manufacture generic drugs feel
that assigning different INNs or creating a new unique naming
system just gives brand name companies the upper hand.226
They claim that establishing separate INNs for biosimilars will
only stunt substitution of the reference product for the biosimi-
lar; arguing that a new naming standard would create confu-
sion for physicians and pharmacists because they will have to
figure out “whether the products are really the same as they
try verifying dosing and requirements.”227
The Generic Pharmaceutical Association (GPA) points out
that current FDA practices allow a reference product to main-
tain the same INN even after the manufacturing process or
220. Letter from Richard Dolinar, Chairman for the All. for Safe Biologic
Med., to Dr. Margaret Hamburg, FDA Comm’r (Apr. 16, 2012) [hereinafter
Dolinar Letter], http://safebiologics.org/pdf/comments/ASBM-Comments.pdf;
see also Letter from Ralph G. Neas, President and CEO Generic Pharm. Ass’n
to FDA (Sept. 17, 2013) [hereinafter GPA Citizens Petition], available at
http://www.regulations.gov/#!documentDetail;D=FDA-2013-P-1153-0001.
221. Silverman, supra note 199.
222. Id.
223. Tracking adverse events is also known as pharmacovigilance, or post-
marketing monitoring. Dolinar Letter, supra note 220, at 2.
224. Id. at 1.
225. Silverman, supra note 199.
226. Id.
227. Id.
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production facility changes.228 Based on the FDA’s reasoning
for providing unique INN for biosimilars, any biologic produced
in another manufacturing plant or with any manufacturing
changes, should also be given a unique INN.229 Additionally,
GPA argues that because all biologics approved under § 351(k)
are highly similar they have no clinically meaningful differ-
ences, and thus should share the same INN as the reference.230
In regards to tracking adverse reactions, the GPA believes a
more narrowly tailored solution will better fix the problem.231
The GPA suggests practitioner education and system en-
hancements would better serve the patients.232 Further, the
GPA stresses that the adoption of unique INNs to identify bio-
similars would frustrate the main purpose of the BPCIA, which
is to create competition in the biologics marketplace.233 On Oc-
tober 23, 2013, a group of bipartisan Senators sent a letter to
FDA Commissioner Hamburg, which stated that “if biosimilars
are unable to share the same active ingredient name as the
brand name originator product, we believe the Congressional
intent behind the BPCIA would be undermined as would the
safety and accessibility of affordable biosimilars.”234 In these
letters, the Senators also addressed the complicated issue of
substitution; arguing that unique naming runs the risk of in-
terfering with many state-generic substitution laws.235 Given
228. GPA Citizens Petition, supra note 220.
229. Biopharmaceuticals are sensitive to environmental changes, and there-
fore manufacturing plays an important role in the development of biophar-
maceuticals. As one scholar noted,
[t]here is a wide variability in the composition and bioactivity of
products produced outside of the United States and Europe. In a
study comparing 11 epoetin products from four different countries
(Korea, Argentina, China, India) the isoform distribution among
these product was variable and there were substantial deviations
from specification for in vivo bioactivity.
Mellstedt et al., supra note 2, at 412.
230. GPA Citizens Petition, supra note 220, at 1.
231. Id. at 3.
232. Id.
233. Id.
234. Letter from Senator John D. Rockefeller IV et al. to FDA Comm’r Dr.
Margaret Hamburg (Oct. 23, 2013),
http://amcp.org/WorkArea/DownloadAsset.aspx?id=17326.
235. Id.
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that generic substitution is a common cost savings tool, it is not
something that “we can afford to lose.”236
The United States is not the only country having this naming
debate; the EU has also voiced a strong opinion about how bio-
similars should be named.237 In October 2013, the European
Commission Pharmaceutical Committee met and discussed the
issues surrounding biosimilar naming.238 The majority of EU-
member states “strongly supported” that biosimilars should
have the same INN as their reference product.239 EU-member
states made arguments similar to the GPA, stating that unique
INNs could undermine the public perception of biosimilars.240
Additionally, EU-member states addressed that traceability is
not an issue because both the brand name and INN are report-
ed, while the batch number is often reported, making it simple
to discover the source for any adverse reactions.241 A report
from the EU in 2013 stated that every medicine would “either
have an invented (trade) name, or the name of the active sub-
stance together with the company name/trademark,” thereby
eradicating the need for a unique INN.242 Clear identification,
the report stated, was important for reporting and monitoring
adverse drug reactions.243 In order to ensure the safety of con-
sumers, the EMEA monitors biosimilar products through both
postmarketing monitoring and risk-management plans identi-
fying products by manufacturer name and batch number.244
Ideally, such additional precautions would allow biosimilars to
share the same INN as its reference product.
236. Id.
237. EU Majority Says Same INNs for Biosimilars, GABI ONLINE (Feb. 28,
2014), http://www.gabionline.net/Biosimilars/General/EU-majority-says-
same-INNs-for-biosimilars.
238. Id.
239. Id.
240. Id.
241. Id.
242. EUROPEAN COMMISSION, WHAT YOU NEED TO KNOW ABOUT BIOSIMILAR
MEDICINAL PRODUCTS 13 (2013), available at
http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_report
_en.pdf.
243. Id.
244. EuropaBio, Naming, Pharmacovigilance and Risk Management Plans,
in GUIDE TO BIOLOGICAL MEDICINES – A FOCUS ON BIOSIMILAR MEDICINES 6
(2011),
http://www.europabio.org/sites/default/files/report/guide_to_biological_medici
nes_a_focus_on_biosimilar_medicines.pdf.
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In response to the FDA’s request for comments, two Europe-
an Associations commented on the EMEA’s approach to biosim-
ilar regulations.245 The comments stated that in the EU certain
biosimilars have an identical INN to the reference product
whereas others have a unique INN.246 The European Associa-
tions stressed the need for authorities to take proper measures
to track the specific biologic products, either reference product
or biosimilar, given to patients.247 In addition, the comments
suggested that the FDA take a simpler approach to ensure pa-
tient safety, such as requiring physicians to prescribe biologics
by the invented or brand name, instead of the INN.248
IV. HOW CAN THE FDA PROMOTE CONFIDENCE IN BIOSIMILAR
PRODUCTS THROUGH NAMING?
The naming convention wherein the same nonproprietary
name is used has proven safe and effective for both small-
molecule and biological drugs in Europe.249 Therefore, “it
should be the standard in the United States.”250 In order for
physicians, pharmacists, and consumers to trust the biosimilar
market, the FDA must reject their most recent guidance that
suggests biosimilars be given a unique suffix to attach to the
INN. This approach will not only confuse healthcare profes-
sionals, but neglect to build trust in the biosimilar market.
The BPCIA’s main goal is to provide affordable biosimilar
drugs to terminally ill patients.251 Therefore, the FDA must not
forget this important objective to create a viable abbreviated
245. EuropaBio, FDA Request for Comments on “Approval Pathway for Bio-
similar and Interchangeable Biological Products” 8 (2010),
http://www.europabio.org/sites/default/files/position/europabio_ebe_joint_sub
mission_to_fda.pdf.
246. Id.
247. Id.
248. Id. at 9.
249. AMCP is Disappointed in FDA’s Draft Guidance and Proposed Rule
Calling for Suffix on Nonproprietary Names of Biological Products, PR
NEWSWIRE (Aug. 27, 2015), http://www.prnewswire.com/news-releases/amcp-
is-disappointed-in-fdas-draft-guidance-and-proposed-rule-calling-for-suffix-
on-nonproprietary-names-of-biological-products-300134442.html.
250. Id.
251. Amanda Potter, Interpreting the BPCIA – Is the “Patent Dance” Man-
datory?, COLUM. SCI. & TECH. L. REV. BLOG (Mar. 31, 2015),
http://stlr.org/2015/03/31/interpreting-the-bpcia-is-the-patent-dance-
mandatory/.
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approval pathway for biosimilars.252 This includes a naming
system that bolsters the use of these biosimilars by healthcare
professionals and patients. In order to maintain the integrity of
the BPCIA’s founding concern, the FDA should adopt a two-
pronged approach to ensure the BPCIA’s success. First, the
FDA must produce a final guidance that assigns biosimilars,
including those found to be interchangeable, the same INN as
their reference counterparts. Second, the FDA must develop a
final guidance allowing biosimilar products to include detailed
and pertinent information through labeling.
A. Step One: A Uniform Naming System
Given the importance of naming, it is crucial that the FDA
modify their current approach and adopt a naming scheme that
balances consumer safety with the expansion of biosimilar use.
The practice of assigning identical INNs to products that are
biosimilar to a reference product will not harm consumers and
will positively impact the use of biosimilars by healthcare pro-
fessionals.
Congress enacted the BPCIA to incentivize development of
biosimilars.253 When the FDA finds a product to be biosimilar it
has analyzed a multitude of clinical results, efficacy studies,
and immunogenicity tests.254 All of these provide analytical da-
ta that the product has no clinically meaningful difference from
the reference product.255 Assigning a unique suffix to a biosimi-
lar conveys that the product has differences from the reference
product and suggests that the product should have been ap-
proved through a different pathway, such as § 351(a).256
Even prior practice dictates that if the FDA finds a product to
be biosimilar, then it should have the same INN.257 Historical-
ly, biologic names that included a prefix or suffix signaled that
252. Id.
253. Blackstone et al., supra note 102, at 469.
254. Gorman et al., supra note 71, at 329.
255. See 42 U.S.C. § 262(k)(2)(A)(i)(II)–(V) (2010).
256. Sumant Ramachandra, Senior Vice President and Chief Scientific Of-
ficer, Hospira, What’s in a Name? 12–13 (2013),
http://www.biologicsblog.com/wp-content/uploads/2015/03/Whats-In-a-Name-
Hospira-Policy-Paper.pdf.
257. Id. at 12. While Hospira, as a biosimilar producer, may be biased, all
assertions from this policy paper referenced herein were fact-checked.
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there were significant differences between products.258 For ex-
ample, interferon, which is a class of proteins, is designated
with the suffix alfa or beta.259 Interferon alfa is used to help
patients with hepatitis or melanoma,260 while interferon beta is
used for treating multiple sclerosis.261 Interferon alfa and inter-
feron beta are actually different at the molecular level and
therefore have different clinical effects on patients.262 In con-
trast, a biosimilar is deemed to have no clinically meaningful
difference when compared to a reference product.263 Therefore,
carrying this practice over to biosimilars will not only confuse
healthcare professionals but ultimately prevent them from pre-
scribing biosimilar products.
The FDA argues INN suffixes are necessary in order to track
adverse events to a specific manufacturer and facilitate the
safe use of the product and protection of patients.264 However,
when a biosimilar has an identical INN to the reference prod-
uct, it still has its own brand name. For example, Sandoz’s
product Zarxio shares the INN “filgrastim,” with Amgen’s
Neupogen.265 In order to prevent confusion a clinician should
prescribe the biosimilar by its unique name Zarxio, instead of
the INN filgrastim. The use of brand names should prevent in-
advertent substitution and will also make postmarketing moni-
toring easier. Postmarketing monitoring can be conducted by
brand name, manufacturer, or specific lot number.266 Using the
brand name to prescribe a biosimilar will help point to a specif-
258. Id.
259. Runkel et al., Differences in Activity Between α and beta β Type 1 In-
terferons Explored by Mutational Analysis, 273 J. BIOLOGICAL CHEMISTRY
8003, 8003 (1998).
260. See generally Interferon alfa-2b, Recombinant Medication Guide,
FDA.GOV (2011),
http://www.fda.gov/downloads/Drugs/DrugSafety/ucm111337.pdf.
261. See generally Interferon beta-1b Betaseron, FDA.GOV (1993),
http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrug
sareDevelopedandAp-
proved/ApprovalApplications/TherapeuticBiologicApplications/ucm087676.pd
f.
262. Runkel, supra note 259 at, 8003.
263. See 42 U.S.C. § 262 (k)(2)(A)(i)(II)–(V) (2010).
264. Naming Guidance, supra note 213.
265. Sukduang et al., supra note 133.
266. Naming Guidance, supra note 213.
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ic manufacturer, which in turn can identify a specific lot num-
ber.
The FDA argues that most passive pharmacovigilance sys-
tems do not include brand names or national drug code num-
bers in any adverse event reports.267 If that is the case, then
the answer is not to adapt a dysfunctional naming system that
thwarts the goals of the legislation that spurred this industry
in the first place. The solution is to adopt a new pharmacovigi-
lance system, one that uses the brand name, manufacturer,
and lot number. This shows both healthcare professionals and
patients the reliability of biosimilar drugs and the FDA’s abil-
ity to achieve comprehensive monitoring. The naming system
established by the FDA was designed to avoid inadvertent sub-
stitution and to ensure the safe use of the product and protec-
tion of patients.268 However, prescribing biosimilars possessing
the brand name, such as Zarxio or Neupogen, can prevent in-
advertent substitution.
B. Step Two: A Detailed Approach to Labeling
Similar to the naming debate, the BPCIA is silent regarding
labeling requirements. The Hatch-Waxman Act mandates that
every ANDA application have labeling that is identical to the
reference product.269 Given the lack of explicit guidance, the
FDA has the sole discretion to determine the labeling guide-
lines.270 The FDA should evaluate each biosimilar on a product-
by-product basis and work with the applicant to propose label-
ing based on the science in the application.271 This will give the
FDA the option, depending on the product, to either approve
the same label, or require a different one. The FDA took simi-
267. Id. at 9.
268. Id. at 9.
269. 21 U.S.C. § 355(j)(2)(A) (1984). Despite this requirement’s existence,
the FDA is authorized to approve ANDAs that omit labeling carried by the
reference product when the label is protected by either patent or exclusivity
See Julie Dohm, Expanding The Scope of the Hatch-Waxman Act’s Patent
Carve-out Exception to the Identical Drug Labeling Requirement: Closing the
Patent Litigation Loophole, 156 U. PA. L. REV. 151, 157 (2007).
270. 21 U.S.C. § 321(n) (1976).
271. Letter from Bruce A. Leicher, Senior Vice President and Gen. Counsel,
Momenta Pharms., to Food & Drug Admin., Division of Dockets Manage-
ment, at 9 (Oct. 27, 2015) [hereinafter Leicher Letter], available at
http://www.biologicsblog.com/wp-
content/uploads/2015/11/Comment_from_Momenta_Pharmaceuticals_Inc.pdf.
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lar action with regards to Sandoz’s Zarxio application.272 With
this application, the FDA carefully reviewed the label and ul-
timately determined that the label was informative and not
misleading.273 It can also be assumed that extraneous factors
affected the FDA’s reasoning. For example, concluding Zarxio
needed a different label would mislead healthcare professionals
into thinking that Zarxio was not an alternative for Neupogen,
but instead an entirely different product.
The FDA should avoid instituting a labeling requirement
wherein a biosimilar application must have a different label
than the reference product. Such labeling requirement would
run contrary to intent of the BPCIA.274 Additionally, such a la-
beling requirement would provide less incentives to drug man-
ufacturers to invest in the production of biosimilars.275 From
the start, biosimilars would be at disadvantage when compared
with the reference product. Even worse, drug manufacturers
would have no incentive to create an interchangeable biosimi-
lar.276 Instead, a product-by-product labeling system is prefera-
ble.277 Through this system, drug manufacturers can choose to
convey certain additional information to clinicians about their
biosimilar product. For example, a drug manufacturer may
want to include that the product is interchangeable and has
been approved for automatic substitution on the label.278
CONCLUSION
Ultimately, the efforts supporting the production of biosimi-
lars have been international. As seen in the EU, countries have
enacted abbreviated pathways with the intention of providing
272. See Sandoz, supra note 124.
273. The FDA decided that any additional information could be found in the
“Purple Book” available on the FDA’s website. Whether the Purple Book is a
sufficient alternative for this type of information is hotly debated. Leicher
Letter, supra note 271, at 9. However, this discussion is beyond the scope of
this Note.
274. That express labeling requirements were not included in the BPCIA
implies that Congress intended to defer to the FDA’s discretion with respect
to best-labeling practices. In addition, the BPCIA was enacted to facilitate
the use of biosimilars, but mandating different labeling prevents such use. 21
U.S.C. § 321(n).
275. Leicher Letter, supra note 271, at 5.
276. Id.
277. Id. at 9.
278. Id. at 9.
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cheaper life-saving biologic medicines to patients. Although the
implications of biosimilar naming are complex and difficult to
navigate, it is important that regulators do not lose sight of the
importance of biosimilar substitution. Requiring biosimilars to
be given new unique INNs is detrimental to the future produc-
tion and distribution of biosimilars. There are numerous ways
that regulators can ensure the safety of patient health through
pharmacovigilance, without each biosimilar receiving a unique
INN. Providing new unique INNs to biosimilars will stunt the
potential of the biosimilars market, will create confusion in the
healthcare system, and effectively undermine the true intent of
the BPCIA. Continuing the use of the small-molecule INN
naming system for biosimilars will prevent yet another misstep
in a market already plagued by confusion, inefficiency, and
high costs.
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